返回 Agenda
SESSION 10: Making the ME(N)A region a Clinical Trials hub
Session Chair(s)
Angelika Joos, MPharm
Executive Director, Science & Regulatory Policy
MSD, Belgium
Marco Rafael, PharmD, MBA, RPh
Regulatory Policy Leader
Roche, Switzerland
Overview This Session will highlight global, regional and local efforts to enhance the Clinical Trials environment. WHO will share how regulatory ecosystem optimisation can be a driver for trial activity, followed by AVAREF exploring cross-country collaboration between regulators and ethics committees. Regulators from Saudi Arabia, Tunisia, Egypt, and the UAE will share national initiatives to strengthen the CTs infrastructure and streamline approvals. The session will close with insights on data quality, patient recruitment, and health literacy in line with ICH and ethical guidelines.
Speaker(s)
National Initiatives for Ecosystem Strengthening, Regulatory Approval Predictability, Collaboration with Ethics Review Boards, Capacity Building and Infrastructure Investment
Marwa Al Abbas
Saudi Food and Drug Authority (SFDA), Saudi Arabia
Senior Clinical Trial Expert
National Initiatives for Ecosystem Strengthening, Regulatory Approval Predictability, Collaboration with Ethics Review Boards, Capacity Building and Infrastructure Investment
Rania Ibrahim
Egyptian Drug Authority (EDA), Egypt
General Manager of The General Administration of Clinical Trials
National Initiatives for Ecosystem Strengthening, Regulatory Approval Predictability, Collaboration with Ethics Review Boards, Capacity Building and Infrastructure Investment
Shaikha Almazrouei
Emirates Drug Establishment (EDE), United Arab Emirates
Director of the Reference National Laboratory – Drug Department
Strengthening Technical Collaboration between Regulators and Ethics Committees across countries under the AMA Framework
Rhanda Adechina Adehan
World Health Organization (WHO), Switzerland
Technical Officer - Consultant AVAREF Secretariat
Panel Discussion with Q&A (with the additional participation of):
Abdul Rouf Palli Valapila, PhD
Hamad Medical Corporation (HMC), Qatar
Director of Operations for Clinical Trial Unit
Panel Discussion with Q&A (with the additional participation of):
Mariem Kadri
ANMPS (Agence Nationale Du Médicaments et des Produits de la santé), Tunisia
Pharmacist - Directorate of Pharmacy and Medicine